Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer
Carcinogenesis · 2024
DOI: 10.1093/carcin/bgae014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2024. Verfasst von Lucas Mani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Vanderbilt University, Nashville, USA. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Antibodies, Monoclonal, Humanized, Xenograft Model Antitumor Assays, ErbB Receptors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Stanford University School of Medicine, Department of Otolaryngology-Head and Neck Surgery, Department of Otolaryngology—Head and Neck Surgery.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) is highly expressed in 80–90% of head and neck squamous cell carcinomas (HNSCCs), making it an ideal target for antibody–drug conjugates. Depatuxizumab mafodotin (ABT-414), is an EGFR-targeting ADC comprised of the monoclonal antibody ABT-806 conjugated to monomethyl auristatin F, a tubulin polymerization inhibitor. This study assessed the in vivo efficacy of ABT-414 in HNSCC. The effects of ABT-414 on HNSCCs were determined using in vitro cytotoxicity assays and in vivo flank xenograft mouse models. The distribution of ABT-414 was assessed ex vivo via optical imaging methods using a conjugate of ABT-414 to the near-infrared agent IRDye800. In vitro treatment of high EGFR-expressing human HNSCC cell lines (UMSCC47 and FaDu) with ABT-414 (0–3.38 nM) resulted in dose-dependent cell death (IC50 values of 0.213 nM and 0.167 nM, respectively). ABT-414 treatment of the FaDu mouse xenografts displayed antitumor activity (P = 0.023) without a change in body mass (P = 0.1335), whereas treatment of UMSCC47 did not generate a significant response (P = 0.1761). Fluorescence imaging revealed ABT-414-IRDye800 accumulation in the tumors of both FaDu and UMSCC47 cell lines, with a signal-to-background ratio of >10. ABT-414 treatment yielded antitumor activity in FaDu tumors, but not in UMSCC47, highlighting the potential for ABT-414 efficacy in high EGFR-expressing tumors. Although ABT-414-IRDye800 localized tumors in both cell lines, the differing antitumor responses highlight the need for further investigation into the role of the tumor microenvironment in drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Vanderbilt University, Nashville, USA.
ORCID-Profile: Lucas Mani
Förderung
- Stanford University School of Medicine
- Department of Otolaryngology-Head and Neck Surgery
- Department of Otolaryngology—Head and Neck Surgery
Zitieren
APA
Mani, L., Naveed, A., McAdoo, A., Rosenthal, E., & Hom, M. (2024). Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgae014
Vancouver
Mani L, Naveed A, McAdoo A, Rosenthal E, Hom M. Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer. Carcinogenesis. 2024. doi:10.1093/carcin/bgae014
BibTeX
@article{Mani2024,
author = {Mani, Lucas and Naveed, Abdullah and McAdoo, Ashtyn and Rosenthal, Eben and Hom, Marisa},
title = {Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer},
journal = {Carcinogenesis},
year = {2024},
doi = {10.1093/carcin/bgae014}
}
EUVIMED